vs
Side-by-side financial comparison of AMC Networks Inc. (AMCX) and Amneal Pharmaceuticals, Inc. (AMRX). Click either name above to swap in a different company.
Amneal Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($722.5M vs $594.8M, roughly 1.2× AMC Networks Inc.). Amneal Pharmaceuticals, Inc. runs the higher net margin — 10.8% vs -9.3%, a 20.1% gap on every dollar of revenue. On growth, Amneal Pharmaceuticals, Inc. posted the faster year-over-year revenue change (3.9% vs -0.8%). Over the past eight quarters, Amneal Pharmaceuticals, Inc.'s revenue compounded faster (1.5% CAGR vs -0.1%).
AMC Networks Inc. is an American independent mass media and entertainment corporation headquartered in 11 Penn Plaza, New York City. The company owns and operates the eponymous cable channel, BBC America, IFC, Sundance TV, and We TV. It also owns the art house movie theater IFC Center in New York City; the independent film companies Independent Film Company and RLJE Films, the anime licensor Sentai Filmworks, the premium subscription streaming services AMC+, IFC Films Unlimited, Acorn TV, All...
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
AMCX vs AMRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $594.8M | $722.5M |
| Net Profit | $-55.5M | $78.0M |
| Gross Margin | 49.7% | 44.3% |
| Operating Margin | -8.6% | — |
| Net Margin | -9.3% | 10.8% |
| Revenue YoY | -0.8% | 3.9% |
| Net Profit YoY | 80.5% | 217.0% |
| EPS (diluted) | $-0.97 | $0.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $722.5M | ||
| Q4 25 | $594.8M | $814.3M | ||
| Q3 25 | $561.7M | $784.5M | ||
| Q2 25 | $600.0M | $724.5M | ||
| Q1 25 | $555.2M | $695.4M | ||
| Q4 24 | $599.3M | $730.5M | ||
| Q3 24 | $599.6M | $702.5M | ||
| Q2 24 | $625.9M | $701.8M |
| Q1 26 | — | $78.0M | ||
| Q4 25 | $-55.5M | $35.1M | ||
| Q3 25 | $76.5M | $2.4M | ||
| Q2 25 | $50.3M | $22.4M | ||
| Q1 25 | $18.0M | $12.2M | ||
| Q4 24 | $-284.5M | $-31.1M | ||
| Q3 24 | $41.4M | $-156.0K | ||
| Q2 24 | $-29.2M | $6.0M |
| Q1 26 | — | 44.3% | ||
| Q4 25 | 49.7% | 36.5% | ||
| Q3 25 | 48.2% | 34.9% | ||
| Q2 25 | 52.7% | 39.5% | ||
| Q1 25 | 51.8% | 36.8% | ||
| Q4 24 | 51.2% | 36.0% | ||
| Q3 24 | 52.0% | 38.4% | ||
| Q2 24 | 55.2% | 35.6% |
| Q1 26 | — | — | ||
| Q4 25 | -8.6% | 13.8% | ||
| Q3 25 | 9.9% | 9.0% | ||
| Q2 25 | 10.7% | 15.4% | ||
| Q1 25 | 11.6% | 14.4% | ||
| Q4 24 | -42.4% | 10.4% | ||
| Q3 24 | 15.6% | 12.6% | ||
| Q2 24 | 1.7% | 13.6% |
| Q1 26 | — | 10.8% | ||
| Q4 25 | -9.3% | 4.3% | ||
| Q3 25 | 13.6% | 0.3% | ||
| Q2 25 | 8.4% | 3.1% | ||
| Q1 25 | 3.3% | 1.8% | ||
| Q4 24 | -47.5% | -4.3% | ||
| Q3 24 | 6.9% | -0.0% | ||
| Q2 24 | -4.7% | 0.9% |
| Q1 26 | — | $0.19 | ||
| Q4 25 | $-0.97 | $0.10 | ||
| Q3 25 | $1.38 | $0.01 | ||
| Q2 25 | $0.91 | $0.07 | ||
| Q1 25 | $0.34 | $0.04 | ||
| Q4 24 | $-6.23 | $-0.10 | ||
| Q3 24 | $0.76 | $0.00 | ||
| Q2 24 | $-0.66 | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $502.4M | — |
| Total DebtLower is stronger | $1.8B | — |
| Stockholders' EquityBook value | $981.9M | — |
| Total Assets | $3.9B | — |
| Debt / EquityLower = less leverage | 1.78× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $502.4M | $282.0M | ||
| Q3 25 | $716.8M | $201.2M | ||
| Q2 25 | $866.4M | $71.5M | ||
| Q1 25 | $870.2M | $59.2M | ||
| Q4 24 | $784.6M | $110.6M | ||
| Q3 24 | $816.4M | $74.0M | ||
| Q2 24 | $802.6M | $43.8M |
| Q1 26 | — | — | ||
| Q4 25 | $1.8B | $2.6B | ||
| Q3 25 | $1.9B | $2.6B | ||
| Q2 25 | $2.2B | $2.2B | ||
| Q1 25 | $2.3B | $2.2B | ||
| Q4 24 | $2.3B | $2.4B | ||
| Q3 24 | $2.3B | $2.4B | ||
| Q2 24 | $2.4B | $2.4B |
| Q1 26 | — | — | ||
| Q4 25 | $981.9M | $-70.8M | ||
| Q3 25 | $1.1B | $-109.5M | ||
| Q2 25 | $971.7M | $-112.1M | ||
| Q1 25 | $888.8M | $-131.7M | ||
| Q4 24 | $855.6M | $-109.3M | ||
| Q3 24 | $1.1B | $-93.4M | ||
| Q2 24 | $1.1B | $-57.5M |
| Q1 26 | — | — | ||
| Q4 25 | $3.9B | $3.7B | ||
| Q3 25 | $4.2B | $3.6B | ||
| Q2 25 | $4.4B | $3.4B | ||
| Q1 25 | $4.3B | $3.4B | ||
| Q4 24 | $4.4B | $3.5B | ||
| Q3 24 | $4.8B | $3.5B | ||
| Q2 24 | $4.9B | $3.5B |
| Q1 26 | — | — | ||
| Q4 25 | 1.78× | — | ||
| Q3 25 | 1.82× | — | ||
| Q2 25 | 2.27× | — | ||
| Q1 25 | 2.62× | — | ||
| Q4 24 | 2.73× | — | ||
| Q3 24 | 2.10× | — | ||
| Q2 24 | 2.26× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $49.2M | — |
| Free Cash FlowOCF − Capex | $40.4M | — |
| FCF MarginFCF / Revenue | 6.8% | — |
| Capex IntensityCapex / Revenue | 1.5% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $272.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $49.2M | $130.3M | ||
| Q3 25 | $44.8M | $118.5M | ||
| Q2 25 | $102.8M | $83.8M | ||
| Q1 25 | $108.8M | $7.4M | ||
| Q4 24 | $58.1M | $118.1M | ||
| Q3 24 | $62.2M | $141.8M | ||
| Q2 24 | $104.4M | $39.7M |
| Q1 26 | — | — | ||
| Q4 25 | $40.4M | $108.5M | ||
| Q3 25 | $42.0M | $106.2M | ||
| Q2 25 | $95.7M | $61.0M | ||
| Q1 25 | $94.2M | $-5.8M | ||
| Q4 24 | $37.6M | $102.9M | ||
| Q3 24 | $53.9M | $124.8M | ||
| Q2 24 | $95.2M | $29.0M |
| Q1 26 | — | — | ||
| Q4 25 | 6.8% | 13.3% | ||
| Q3 25 | 7.5% | 13.5% | ||
| Q2 25 | 16.0% | 8.4% | ||
| Q1 25 | 17.0% | -0.8% | ||
| Q4 24 | 6.3% | 14.1% | ||
| Q3 24 | 9.0% | 17.8% | ||
| Q2 24 | 15.2% | 4.1% |
| Q1 26 | — | — | ||
| Q4 25 | 1.5% | 2.7% | ||
| Q3 25 | 0.5% | 1.6% | ||
| Q2 25 | 1.2% | 3.2% | ||
| Q1 25 | 2.6% | 1.9% | ||
| Q4 24 | 3.4% | 2.1% | ||
| Q3 24 | 1.4% | 2.4% | ||
| Q2 24 | 1.5% | 1.5% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.72× | ||
| Q3 25 | 0.59× | 50.00× | ||
| Q2 25 | 2.04× | 3.74× | ||
| Q1 25 | 6.03× | 0.61× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.50× | — | ||
| Q2 24 | — | 6.62× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMCX
| Subscription And Circulation | $314.8M | 53% |
| Advertising | $124.9M | 21% |
| Other | $79.1M | 13% |
| License | $74.8M | 13% |
| Related Party | $1.2M | 0% |
AMRX
| Affordable Medicines net | $423.0M | 59% |
| AvKARE net | $166.0M | 23% |
| Specialty net | $133.0M | 18% |
